Astellas Pharma (ALPMY) Stock News

Mitsubishi Research Institute (MRI) and Astellas Pharma (ALPMY) have announced a strategic collaboration to support Japanese drug-discovery startups in their global expansion efforts. The partnership, formalized through a memorandum of understanding, operates under the Ministry of Health's MEDISO program, which MRI has managed since 2018. Through this initiative, participating startups will gain access to laboratory and office space at Astellas' SakuLab™-Tsukuba facility, along with expert consultations and networking opportunities. MRI will leverage its experience of supporting over 1,200 startup and academic ventures to design specific support programs, while Astellas will provide industry expertise and resources. This collaboration aligns with Japan's Basic Policy on Economic and Fiscal Management and Reform 2024, aiming to strengthen the country's position as a global drug discovery hub.

Astellas Pharma has entered into an exclusive worldwide license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage antibody-drug conjugate targeting CLDN18.2, excluding China's mainland, Hong Kong, Macao and Taiwan region. The deal includes a $130 million upfront payment, up to $70 million in near-term payments, and potential milestone payments totaling $1.34 billion plus royalties. XNW27011, currently in Phase 1/2 trials, has shown promising efficacy in treating solid tumors including gastric, gastroesophageal, and pancreatic cancers. The drug uses a proprietary topoisomerase I inhibitor payload and linker technology, complementing Astellas' existing CLDN18.2 expertise, including their approved therapy VYLOY.

Astellas (ALPMY) has announced its second annual Patient Advocacy Organization (PAO) Action Week™, scheduled for June 9-13, 2025. The initiative, coordinated by Astellas' Patient Centricity team volunteers, aims to connect patients and caregivers with essential resources from over 1,200 PAOs in the U.S. Following the successful inaugural event in 2024, this year's campaign focuses on raising awareness about PAOs' crucial role in providing disease education, support groups, and advocacy for treatment access and research funding.

The event brings together life sciences companies, healthcare organizations, and patient advocacy groups to enhance awareness and accessibility of PAO resources. Organizations can register to participate through the PAO Action Week website (paoactionweek.com/join-us), and stakeholders can follow the campaign through #PAOActionWeek on social media.

Astellas and Pfizer announced significant five-year follow-up results from the Phase 3 ARCHES trial for XTANDI™ (enzalutamide) in treating metastatic hormone-sensitive prostate cancer (mHSPC). The study showed that XTANDI plus androgen deprivation therapy (ADT) reduced death risk by 30% compared to placebo plus ADT. After 61.4 months median follow-up, XTANDI plus ADT demonstrated 66% survival probability at five years versus 53% with placebo plus ADT. The drug showed particular effectiveness in high-volume disease patients, with a 36-month improvement in median overall survival. Additionally, eight-year data from the ENZAMET study revealed that XTANDI plus testosterone suppression achieved median overall survival of 8.0 years compared to 5.8 years in the control group. XTANDI has treated over one million patients globally since its 2012 approval.

Astellas Pharma (ALPMY) and MBC BioLabs have announced DeepSeq.AI and Serna Bio as the winners of the 2025 Astellas Future Innovator Prize. Selected from over 50 applications, both companies will receive one-year priority access to MBC BioLabs' state-of-the-art facility in San Francisco, along with access to Astellas' R&D capabilities and business expertise.

The winners were chosen based on their innovative approaches, therapeutic potential, and platform scalability. DeepSeq.AI focuses on oncology and infectious diseases, while Serna Bio specializes in CNS research. This marks the sixth year of the award program, which aims to support early-stage life-science companies in advancing their research into viable treatments.

Astellas Pharma will present 16 abstracts at the 2025 ASCO Annual Meeting (May 30 - June 3), showcasing new data across its cancer therapies. Key highlights include:

For XTANDI (enzalutamide): New post hoc analyses of long-term overall survival data, including the ARCHES five-year follow-up OS analysis in metastatic hormone-sensitive prostate cancer patients. The ENZAMET trial will present eight-year data comparing enzalutamide vs non-steroidal anti-androgen.

For PADCEV (enfortumab vedotin): Two analyses from the phase 3 EV-302 study in previously untreated locally advanced or metastatic urothelial carcinoma, featuring an exploratory analysis of responders and long-term subgroup analysis.

The presentations emphasize Astellas' focus on long-term overall survival data and clinical outcomes that matter to patients in advanced prostate and bladder cancers.

Astellas Pharma has announced significant changes to its Board of Directors, to be proposed at the 20th Term Annual Shareholders Meeting on June 19, 2025. The company has nominated two new outside directors: Andreas Busch, currently Chief Innovation Officer at Absci Corporation, and Mark Enyedy, Non-Executive Director at BioMarin Pharmaceutical Inc. Both candidates bring extensive global pharmaceutical industry experience. The board will include reelected members such as Kenji Yasukawa as Chairman and Naoki Okamura as President and CEO. The proposed changes aim to enhance board diversity and strengthen its supervisory function, responding to stakeholder feedback.

Astellas Pharma will present nine new research abstracts on geographic atrophy (GA) at two major ophthalmology conferences: the ARVO Annual Meeting (May 4-8, 2025) and Retina World Congress (May 8-11, 2025). The presentations focus on data from GATHER Phase 3 studies of IZERVAY™ (avacincaptad pegol), their FDA-approved C5 inhibitor for GA treatment. Key highlights include analyses of biomarkers, patient experiences across multiple countries, disease mechanisms, and structure-function relationships in GA progression. The research particularly emphasizes the relationship between ellipsoid zone integrity and visual outcomes, along with studies examining patient quality of life in the US, Spain, Germany, and France.

Astellas Pharma (ALPMY) and YASKAWA Electric have signed a definitive agreement to establish a joint venture focused on developing a cell therapy manufacturing platform using YASKAWA's dual-arm robot 'Maholo'. The collaboration aims to address key challenges in cell therapy commercialization, particularly regarding manufacturing accuracy and reproducibility.

The joint venture will combine Astellas' expertise in cell therapy R&D and manufacturing with YASKAWA's robotic technology. The platform will be made accessible to startups and academic institutions to foster innovation in cell therapy development. The initiative addresses industry-wide challenges including the need for skilled workforce and complex technology transfer requirements.

The establishment of the joint venture, following a May 2024 memorandum of agreement, is subject to regulatory approvals and other closing conditions.